All results / Stories / Stephanie Henkel


California Resources Joins Reverse Split Parade

ENERGY: Oil companies avoid penny stock status, wait for price rebound.

California Resources Corp. is the latest in series of energy reverse stock splits.

MannKind Proposes Reverse Stock Split

MannKind Corp. plans a reverse stock split to remain listed on the Nasdaq Stock Market, pending shareholder approval.

CRC Reverse Splits Its Stock

Oil and gas producer California Resources Corp. on Wednesday announced that after the market closed on Tuesday, a 1-for-10 reverse stock split went into effect, where each 10 shares of the Chatsworth company’s outstanding common stock now equal 1 share of common stock.

MannKind Receives $1 Million Milestone Payment

Valencia biotech MannKind Corp. on Tuesday announced that it has received a $1 million milestone payment from Receptor Life Sciences Inc. of Seattle for completing initial formulation studies.

MannKind Faces Delisting, Shares Slump

MannKind Corp. on Friday announced that it has received a delisting notice from the Nasdaq stock exchange, as the company has traded below $1 for more than 30 days.

Amgen Buys Myeloma Drug

Amgen Inc. has acquired worldwide development and commercial rights for a phase-1 multiple myeloma drug from German pharmaceutical company Boehringer Ingelheim, the companies announced Thursday.

Reports: Rams Start Spring Training at Cal Lutheran

Next Monday, the Los Angeles Rams will begin the team’s first offseason training program at California Lutheran University in Thousand Oaks.

Despite Reverse Split, MannKind’s Stock Drops

MannKind Corp.’s post-split stock had a difficult initial day of trading on the market Friday, closing down nearly 13 percent.

ImmunoCellular Files for $13 Million Secondary Offering

ImmunoCellular Therapeutics Ltd. on Monday filed a preliminary prospectus to offer up to 60 million shares of common stock, which the company anticipates will raise approximately $12.8 million in net proceeds.

Software Firm’s Strong Growth

Calabasas software firm NetSol Technologies reported a significant increase in net revenues in its 2016 fiscal second quarter, which the company attributes to growth in its services.

MannKind Barely Misses Estimates

MannKind Corp. (MNKD) announced its second quarter financial results on Monday, reporting an adjusted net loss of $30 million (-7 cents a share) for the second quarter ended June 30, compared with an adjusted net loss of $28.9 million (-7 cents) for the same quarter a year ago.

Simulations Plus Buys Liver Software Firm

Drug simulation software developer Simulations Plus Inc. announced Monday that it is acquiring Dilisym Services Inc. of Research Triangle Park, N.C. in a stock purchase agreement worth up to $10 million.

MannKind Passes $1 Million Research Milestone

PHARMA: Payment comes from partnership to develop inhalable drugs.

Valencia biotech MannKind Corp. received a $1 million milestone payment for completing initial formulation studies.

Hospitals, Insurer Form Cost-Cutting Partnership

PROVIDER: Narrow-network plan will offer employers ‘value-based care’ option.

In an effort to lower costs for employers, health insurer Aetna Inc. of Hartford, Conn. and Providence Health & Services of Renton, Wash., have partnered to create a medical network called Aetna Whole Health in L.A. County.

Amgen Settles $95 Million Lawsuit

Amgen Inc. will pay $95 million to settle a class action lawsuit, the company announced Wednesday.

Study Confirms Effectiveness of Amgen Osteoporosis Drug

Amgen Inc. and UCB Inc. have released results from their Phase III FRAME study of osteoporosis medication Romosozumab.

Baxalta to Lay Off 100 in Thousand Oaks

Illinois biotech Baxalta announced Tuesday that the company will lay off approximately 239 employees, starting with 100 at its Thousand Oaks office, according to the Pacific Coast Business Times.

Kythera Lays Off 117 Workers

Kythera Biopharmaceuticals Inc. is permanently laying off 117 of its employees.

FDA Approves Amgen's Humira Biosimilar

Amgen Inc.’s biosimilar to top-selling drug Humira was approved Friday by the U.S. Food and Drug Administration.

Oil Company Ups Interest Through Debt Swap

ENERGY: Stock tumbles as CRC looks for stability amid industry struggles.

Oil company based in Chatsworth struggles as crude prices have dropped significantly over the past year.